Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

Clinical Infectious Diseases

Volumn 43, Issue 1, 2006, Pages 99-102

  Rauch, A ^a,b   Nolan, D ^a   Martin, A ^a   McKinnon, E ^a   Almeida, C ^a   Mallal, Simon ^a,c  

^a Centre for Clinical Immunology and Biomedical Statistics   (Australia)

^b UNIVERSITY OF BERN   (Switzerland)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; HLA B ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALLELE; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; VESICULAR RASH; VOMITING;

ADULT; ANTI-HIV AGENTS; AUSTRALIA; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; GENETIC SCREENING; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 33745295856     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504874     Document Type: Article

References (11)

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-14.
2. Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 2004; 38:2171-2.
3. Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003; 4:321-4.
4. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.
5. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-2.
6. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101:4180-5.
7. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. CNA30032 Study Team. Pharmacogenomics 2004; 5:203-11.
8. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979-81.
9. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; 8:36-41.
10. Peyriere H, Guillemin V, Lotthe A, et al. Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother 2003; 37:1392-7.
11. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005; 65:285-302.